335 related articles for article (PubMed ID: 10099565)
1. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
2. Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor.
Yazdi PT; Wenning LA; Murphy RM
Cancer Res; 1995 Sep; 55(17):3763-71. PubMed ID: 7641191
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates.
Yazdi PT; Murphy RM
Cancer Res; 1994 Dec; 54(24):6387-94. PubMed ID: 7987833
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding.
Sung C; Youle RJ; Dedrick RL
Cancer Res; 1990 Nov; 50(22):7382-92. PubMed ID: 2224866
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells.
Wenning LA; Yazdi PT; Murphy RM
Biotechnol Bioeng; 1998 Feb; 57(4):484-96. PubMed ID: 10099226
[TBL] [Abstract][Full Text] [Related]
6. The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography.
Sung C; Dedrick RL; Hall WA; Johnson PA; Youle RJ
Cancer Res; 1993 May; 53(9):2092-9. PubMed ID: 8481911
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors.
Martell LA; Agrawal A; Ross DA; Muraszko KM
Cancer Res; 1993 Mar; 53(6):1348-53. PubMed ID: 8443815
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen.
Chan MC; Murphy RM
Cancer Immunol Immunother; 1999 Feb; 47(6):321-9. PubMed ID: 10203062
[TBL] [Abstract][Full Text] [Related]
9. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
10. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
11. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
Laske DW; Ilercil O; Akbasak A; Youle RJ; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):520-6. PubMed ID: 8113865
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxin resistance in multidrug resistant cells.
McGrath MS; Rosenblum MG; Philips MR; Scheinberg DA
Cancer Res; 2003 Jan; 63(1):72-9. PubMed ID: 12517780
[TBL] [Abstract][Full Text] [Related]
15. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
Rosenblum MG; Murray JL; Cheung L; Rifkin R; Salmon S; Bartholomew R
Mol Biother; 1991 Mar; 3(1):6-13. PubMed ID: 1906286
[TBL] [Abstract][Full Text] [Related]
16. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
17. Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.
Colombatti M; Dell'Arciprete L; Chignola R; Tridente G
Cancer Res; 1990 Mar; 50(5):1385-91. PubMed ID: 2302703
[TBL] [Abstract][Full Text] [Related]
18. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive effects of anti-transferrin receptor immunotoxin in a multicellular tumor spheroid model.
Chignola R; Foroni R; Candiani C; Franceschi A; Pasti M; Stevanoni G; Anselmi C; Tridente G; Colombatti M
Int J Cancer; 1994 Apr; 57(2):268-74. PubMed ID: 8157364
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
